-- Convatec Group (CTEC.L) on Thursday detailed its new strategic plan to help achieve its aims of fast-tracking "sustainable and profitable" growth and reaching recently upgraded midterm revenue goals.
In a same-day release, the medical products and technologies company said its Accelerate strategy marks the next stage of its growth ambitions and builds on its FISBE framework, which stands for focus, innovation, simplify, build, and execute.
The new strategy is structured around four pillars, including customer-focused growth, the use of its innovation pipeline and artificial intelligence technology to address patient needs, as well as culture, purpose and performance. The fourth strategic cornerstone, execution excellence, is focused on rapid, "right first time, on-time on-budget" delivery and shortened innovation cycle timelines to streamline operations, improve productivity and meet its goals.
"Convatec delivers innovative medical solutions to improve the lives of millions of people living with chronic conditions. The opportunity for future growth is substantial. Our Accelerate strategy is how we will deliver the next chapter of Convatec's exciting story," Chief Executive Officer Jonny Mason said.
The group's medium-term outlook now targets an annual organic revenue growth of between 6% and 8%, up from the prior 5% to 7% range. Convatec projects its infusion care unit to grow by double digits, as it expects mid-to-high single-digit growth for its advanced wound care, ostomy care, and continence care divisions.
Additionally, the group guided to an adjusted operating margin of between 24% and 26% by 2027, compared with 22.3% in 2025. It also expects "sustainable" double-digit adjusted annual EPS growth and a double-digit free cash flow to equity compound annual growth rate.
The London-listed stock was nearly 3% in the red by Thursday midday trade.